1. Home
  2. XBIT vs BWAY Comparison

XBIT vs BWAY Comparison

Compare XBIT & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XBiotech Inc.

XBIT

XBiotech Inc.

HOLD

Current Price

$2.48

Market Cap

73.2M

Sector

Health Care

ML Signal

HOLD

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

HOLD

Current Price

$17.06

Market Cap

337.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XBIT
BWAY
Founded
2005
2003
Country
United States
Israel
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
73.2M
337.9M
IPO Year
2015
2019

Fundamental Metrics

Financial Performance
Metric
XBIT
BWAY
Price
$2.48
$17.06
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$23.50
AVG Volume (30 Days)
73.6K
59.5K
Earning Date
11-12-2025
11-11-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
213.09
EPS
N/A
0.13
Revenue
N/A
$49,094,000.00
Revenue This Year
N/A
$330.76
Revenue Next Year
N/A
$22.24
P/E Ratio
N/A
$52.44
Revenue Growth
N/A
27.08
52 Week Low
$2.09
$7.84
52 Week High
$7.24
$18.18

Technical Indicators

Market Signals
Indicator
XBIT
BWAY
Relative Strength Index (RSI) 49.98 52.00
Support Level $2.40 $16.75
Resistance Level $2.59 $18.18
Average True Range (ATR) 0.15 0.74
MACD 0.01 0.01
Stochastic Oscillator 45.24 55.86

Price Performance

Historical Comparison
XBIT
BWAY

About XBIT XBiotech Inc.

XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: